Health Care · Pharmaceutical Preparations

EBS Emergent BioSolutions Inc. SEC Filings & Insider Trading Activity 2026

company
CIK 1367644115 filings
Russell 2000

EBS at a glance

Emergent BioSolutions Inc. (EBS, SEC CIK 1367644) filed its latest 10-K annual report on February 27, 2026, a 10-Q quarterly report on November 3, 2026, an 8-K current report on November 4, 2026 and Form 4 insider filings as recently as October 7, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), Emergent BioSolutions Inc. (EBS) reported revenue of $742.9 million (down 28.8% from FY2024) and net income of $52.6 million. Diluted EPS was $0.93.
  • As of September 30, 2026, 28 institutional investment managers tracked by SignalX reported holding Emergent BioSolutions Inc. (EBS) shares worth $147.9 million in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by DeGolyer Donald W on October 7, 2026 of 17,800 shares at $7.09 per share.
  • In the last 90 days, EBS insiders reported 0 open-market purchases ($0) and 2 open-market sales ($146K) on Form 4, a net sale of $146K.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$742.9M
−28.8% vs prior year
Insiders · 90 days
0 buys · 2 sells
Net −$146K
13F holders
28 funds
$147.9M · +1 vs prior quarter
Latest 8-K
Nov 4, 2026
Item 8.01

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Risk Factors

  • Third-party manufacturing: FDA noncompliance could halt sole-source production and interrupt customer supply
  • NARCAN competition: Teva, Padagis and Amneal generics could erode sales through lower-priced or free alternatives
  • Restructuring plan: August 5, 2026 workforce reductions and wet-laboratory closures may disrupt operations
  • Political and social pressures: USG preference for U.S.-made products may reduce Winnipeg facility purchases
  • Restructuring compliance: Workforce reductions may trigger wrongful-termination or discrimination claims under local labor laws

Management Discussion & Analysis

  • Revenue $110.0M, down 52% YoY from $231.1M
  • Gross margin 14% vs 54% YoY, operating loss $37.3M vs income $76.5M
  • Best segment Anthrax MCM, revenue $25.1M, up $23.7M; worst Smallpox MCM, $26.7M, down 68%
  • Cash and equivalents $175.7M vs $205.4M at December 31; operating cash flow $122.4M
  • Debt repurchases $75.0M principal, $68.1M cash; management expects continued quarterly variability and cites NARCAN pricing and volume pressure

AI summary of the EBS 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 4, 2026Full analysis →

Item 8.01: Other Events

  • Up to $22.3 million BioThrax order modification from the U.S. Department of War
  • Approximately $7.4 million first delivery begins in 2026, remaining deliveries expected in 2027

Item EX-99.1: Item EX-99.1

  • Up to $22.3 million BioThrax delivery-order modification from the U.S. Department of War
  • Approximately $7.4 million initial delivery scheduled for 2026, with remaining deliveries expected in 2027
Filed Nov 2, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Emergent BioSolutions announced financial and operating results for the quarter ended September 30, 2026
  • Detailed results and management commentary appear in furnished Exhibit 99.1, the company’s earnings press release

Item 7.01: Regulation FD Disclosure

  • Earnings call scheduled November 2, 2026, covering results for quarter ended September 30, 2026
  • Earnings Call Slides furnished as Exhibit 99.2, providing investor presentation materials for the quarterly results discussion

Item EX-99.2: Item EX-99.2

  • Q3 2026 revenue $110M, within prior guidance, but YTD revenue fell to $500M from $594M
  • FY 2026 guidance reduced to revenue $600M-$645M and Adjusted EBITDA $110M-$140M

Item EX-99.1: Item EX-99.1

  • Q3 revenue $110.0M, down 52% year over year, with Smallpox MCM down 68% and Other Products down 87%
  • Net loss $32.7M, adjusted net loss $18.7M, and adjusted EBITDA loss $4.6M, signaling sharply weaker profitability
Filed Oct 16, 2026Full analysis →

Item 5.02: Departure/Appointment of Directors or Principal Officers

  • CFO Richard Lindahl departs December 31, 2026, then advises through March 31, 2027, supporting 2026 Form 10-K preparation
  • Treasurer Frank Vargo becomes Interim CFO and principal financial and accounting officer January 1, 2027

Item EX-99.1: Item EX-99.1

  • CFO Richard S. Lindahl retires December 31, 2026 after nearly nine years at Emergent
  • Treasurer Frank Vargo becomes interim CFO January 1, 2027, signaling internal succession and near-term continuity

AI summaries of EBS 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for EBS

Don't miss the next EBS filing

  • Alerts as it files. A push when EBS files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut EBS, by share count.
  • Ask anything. An AI agent that reads every EBS filing and answers with sources.

EBS alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
DeGolyer Donald WSellOct 7, 2026$7.09
Williams Paul AnthonySellOct 1, 2026$6.53
Williams Paul AnthonySellJul 1, 2026$8.40
Glessner ColeenFJun 8, 2026$8.00
Hartzel WilliamFJun 8, 2026$8.00
Williams Paul AnthonyFJun 8, 2026$8.00
LINDAHL RICHARD SFJun 8, 2026$8.00
Dayal Sujata TyagiSellMay 1, 2026$8.36

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue$1.0B$1.0B$742.9M
Operating Income--$108.7M$100.1M
Net Income--$190.6M$52.6M
Op. Margin--10.4%13.5%
Net Margin--18.3%7.1%
Balance Sheet
Total Assets$1.8B$1.4B$1.3B
Equity$649.3M$482.8M$522.6M
ROE--39.5%10.1%
Per Share
EPS-$-3.60$0.93
Cash Flow
Operating CF-$58.7M$170.6M
CapEx$51.6M$22.9M$13.8M

Source: XBRL data in Emergent BioSolutions Inc. (EBS)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate EBS share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
EBS shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202628$147.9M
Q2 202627$186.1M
Q1 202628$172.5M
Q4 202527$236.3M
Q3 202528$158.7M
Q2 202526$113.2M
Q1 202521$71.0M
Q4 202418$115.5M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 203 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

EBS filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
8-KNov 4, 2026Analysis-
10-QNov 3, 2026Analysis
8-KNov 2, 2026Analysis-
8-KOct 16, 2026Analysis-
4Oct 7, 2026--
4Oct 5, 2026--
8-KSep 14, 2026Analysis-
8-KSep 1, 2026Analysis-
SC 13GAug 14, 2026-
10-QAug 6, 2026Analysis
8-KAug 5, 2026Analysis-
4Jul 2, 2026--
8-KJun 29, 2026Analysis-
4Jun 10, 2026-
4Jun 10, 2026-
4Jun 10, 2026-
4Jun 10, 2026-
4May 4, 2026--
4May 4, 2026--
4May 4, 2026--
4May 4, 2026--
4May 4, 2026--
4May 4, 2026--
4May 4, 2026--
4May 4, 2026--

Related Health Care companies

All Health Care →

EBS SEC filings: frequently asked questions

Are EBS insiders buying or selling?

In the last 90 days, Emergent BioSolutions Inc. (EBS) officers, directors and 10% owners reported no open-market purchases and 2 open-market sales worth $145,792 by 2 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold EBS stock?

As of September 30, 2026, the largest Emergent BioSolutions Inc. (EBS) holders among the 13F filers tracked by SignalX were BlackRock ($34.1 million), State Street Corp ($17.9 million), Dimensional Fund Advisors ($16.9 million), Vanguard Capital Management LLC ($14.3 million), Millennium Management ($12.4 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was EBS's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), Emergent BioSolutions Inc. (EBS) reported revenue of $742.9 million (down 28.8% from FY2024) and net income of $52.6 million. Diluted EPS was $0.93. The figures come from the XBRL data in the 10-K.

What did EBS report in its latest 8-K?

Emergent BioSolutions Inc. (EBS) filed an 8-K on November 4, 2026 reporting Item 8.01 (Other Events). Up to $22.3 million BioThrax order modification from the U.S. Department of War.

What are the latest EBS SEC filings?

Emergent BioSolutions Inc. (EBS) filed its latest 10-K annual report on February 27, 2026, a 10-Q quarterly report on November 3, 2026, an 8-K current report on November 4, 2026 and a Form 4 insider filing on October 7, 2026.

What is EBS's SEC CIK number?

Emergent BioSolutions Inc. (EBS)'s SEC Central Index Key (CIK) is 1367644. EDGAR lists every EBS filing under that number.

Ask anything about EBS

The research agent reads EBS's filings, financials, insider trades and 13F holders, then answers with sources.